Tarsus Pharmaceuticals, Inc. (TARS): Cash & Equivalents
$183.64M
As of 2025-12-31
$204.59M
As of 2026-06-30
+36.8%
3-year compound annual growth
+1.8%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $183.64M | +93.7% | 2026-02-23, Balance as of period end |
| 2024-12-31 | $94.82M | -57.8% | 2026-02-23, Balance as of period end |
| 2023-12-31 | $224.95M | +213.9% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $71.66M | -58.2% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $171.33M | +1.9% | 2023-03-17, Balance as of period end |
| 2020-12-31 | $168.13M | +190.1% | 2022-03-14, Balance as of period end |
| 2019-12-31 | $57.95M | n/a | 2021-03-31, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $183.64M | +93.7% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $467.71M | +2.6% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $87.63M | -15.0% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $496.30M | +43.9% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $183.05M | -19.1% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $70.50M | +47.1% |
| Vericel Corp (VCEL) | 2025-12-31 | $100.09M | +34.3% |
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $163.08M | +41.0% |
Compare TARS, IMCR, ADMA, KRYS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗